Haleon reported operating profits grow 22% in H1
20th Sep 2022 07:03
(Sharecast News) - Consumer healthcare company Haleon saw operating profits grow more than 20% in the six months ended 30 June, driven by increased profits and margins.
Read moreRBC Capital starts Haleon at 'sector perform'
16th Aug 2022 10:40
(Sharecast News) - RBC Capital Markets initiated coverage of GlaxoSmithKline's consumer health spinoff Haleon on Tuesday at 'sector perform' with a 300p price target.
Read moreGSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims
12th Aug 2022 07:26
(Sharecast News) - GlaxoSmithKline said on Friday that it would "vigorously defend" all claims related to its discontinued heartburn drug Zantac.
Read moreGSK, Haleon, Sanofi slump amid Zantac litigation woes
11th Aug 2022 12:35
(Sharecast News) - Shares in GlaxoSmithKline, Haleon and Sanofi tumbled on Thursday amid concerns about legal proceedings related to Glaxo's former blockbuster heartburn drug Zantac.
Read moreDirector dealings: Haleon non-execs spend over £0.5m between them
3rd Aug 2022 15:42
(Sharecast News) - Consumer products giant Haleon found itself on the list of director deals on Wednesday, after two of its non-executive directors bought more than half a million pounds worth of shares between them.
Read moreHaleon H1 revenues climb
27th Jul 2022 07:08
(Sharecast News) - Healthcare group Haleon said on Wednesday that revenues had climbed in the six months ended 30 June, principally driven by organic revenue growth, higher prices, and an improved volume mix.
Read moreCredit Suisse starts Haleon at 'outperform'
19th Jul 2022 13:06
(Sharecast News) - Credit Suisse has initiated coverage of Haleon, GlaxoSmithKline's recently spun out consumer healthcare arm, at 'outperform' with a 368p price target.
Read more